Patents Issued in October 10, 2017
-
Patent number: 9782405Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: November 17, 2015Date of Patent: October 10, 2017Assignee: Genentech, Inc.Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young
-
Patent number: 9782406Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.Type: GrantFiled: August 19, 2015Date of Patent: October 10, 2017Assignees: Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co., Ltd.Inventors: Zhengying Pan, Xitao Li
-
Patent number: 9782407Abstract: The present invention provides a method for treating or preventing a condition or disease in a human or an animal subject wherein the condition or disease is associated with lipoprotein metabolism, the method comprising administering to the subject a composition comprising benzylamine compounds.Type: GrantFiled: April 15, 2015Date of Patent: October 10, 2017Assignee: DR. REDDY'S LABORATORIES LTD.Inventors: Anima Baruah, Dibyendu De, Ish Kumar Khanna, Sivaram Pillarisetti, Santanu Maitra, Christopher W. Alexander, Jennepalli Sreenu, Indu Dager, Shanavas Alikunju
-
Patent number: 9782408Abstract: The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.Type: GrantFiled: October 6, 2015Date of Patent: October 10, 2017Assignee: Vertex Pharmaceuticals IncorporatedInventors: Mark Thomas Miller, Corey Anderson, Vijayalaksmi Arumugam, Brian Richard Bear, Hayley Marie Binch, Jeremy J. Clemens, Thomas Cleveland, Erica Conroy, Timothy Richard Coon, Bryan A. Frieman, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Sara Sabina Hadida Ruah, Haripada Khatuya, Pramod Virupax Joshi, Paul John Krenitsky, Chun-Chieh Lin, Gulin Erdogan Marelius, Vito Melillo, Jason McCartney, Georgia McGaughey Nicholls, Fabrice Jean Denis Pierre, Alina Silina, Andreas P. Termin, Johnny Uy, Jinglan Zhou
-
Patent number: 9782409Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.Type: GrantFiled: October 23, 2014Date of Patent: October 10, 2017Assignee: The University of ManchesterInventors: Ian Hampson, Lynne Hampson
-
Patent number: 9782410Abstract: The disclosed subject matter provides methods using and kits comprising a compound of formula (I) or a hydrate, a solvate, or a pharmaceutically acceptable salt thereof. The disclosed subject matter further provides a method of treating one or more symptoms of cancer comprising administering to a subject in need thereof a compound of formula (I) and a process for preparing such.Type: GrantFiled: June 9, 2016Date of Patent: October 10, 2017Assignee: REXAHN PHARMACEUTICALS, INC.Inventors: Young B. Lee, Deog J. Kim, Reza Mazhari, Godefridus J. Peters, Dzjemma Sarkisjan
-
Patent number: 9782411Abstract: {4-[5-(3-chloro-phenoxy)-oxazolo[5,4-d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid or a pharmaceutically acceptable salt thereof for use in the prevention or treatment of AKI (acute kidney injury). Medicament and pharmaceutical composition thereof.Type: GrantFiled: October 15, 2014Date of Patent: October 10, 2017Assignee: SANOFIInventors: Véronique Briand, Sabine Gratzer, Thomas Huebschle, Philip Janiak, Dieter Kadereit, Ashfaq Parkar, Bruno Poirier, Matthias Schaefer, Paulus Wohlfart
-
Patent number: 9782412Abstract: Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound represented by Formula (I), where R1 to R3, W, X, Y, Z, and n represent those as defined in the specification, or a salt thereof, as an active ingredient.Type: GrantFiled: October 19, 2016Date of Patent: October 10, 2017Assignee: TAIHO PHARMACEUTICAL CO., LTD.Inventors: Fumihito Hosoi, Yoshinori Nakachi, Daisuke Kajiwara
-
Patent number: 9782413Abstract: The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid and its use for the treatment of essential thrombocythemia.Type: GrantFiled: October 21, 2016Date of Patent: October 10, 2017Assignee: AOP ORPHAN PHARMACEUTICALS ACInventors: Rudolf Widmann, Georg Strieder
-
Patent number: 9782414Abstract: A novel crystalline form of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutical compositions containing said crystalline form and the use of said crystalline form in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection are disclosed. In some embodiments, the novel crystalline form comprises a stable polymorph of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate. The present invention is further directed to a process for the preparation of the novel crystalline form.Type: GrantFiled: January 5, 2017Date of Patent: October 10, 2017Assignee: Array BioPharma, Inc.Inventors: Alisha B. Arrigo, Derrick Juengst, Khalid Shah
-
Patent number: 9782415Abstract: Compounds of Formula I: and salts thereof in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification, are inhibitors of Trk kinases and are useful in the treatment of diseases which can be treated with a Trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.Type: GrantFiled: January 9, 2017Date of Patent: October 10, 2017Assignee: Array BioPharma, Inc.Inventors: Shelley Allen, Steven W. Andrews, Kevin Ronald Condroski, Julia Haas, Lily Huang, Yutong Jiang, Timothy Kercher, Jeongbeob Seo
-
Patent number: 9782416Abstract: Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.Type: GrantFiled: August 12, 2014Date of Patent: October 10, 2017Assignee: Essentialis, Inc.Inventor: Neil Madison Cowen
-
Patent number: 9782417Abstract: The invention provides methods for inducing, enhancing or increasing satellite cell proliferation, and an assay for screening for a candidate compound for inducing, enhancing or increasing satellite cell proliferation. Also provided are methods for repairing or regenerating a damaged muscle tissue of a subject.Type: GrantFiled: February 1, 2016Date of Patent: October 10, 2017Assignee: Presidents and Fellows of Harvard CollegeInventors: Lee L. Rubin, Amanda Gee, Amy J. Wagers
-
Patent number: 9782418Abstract: The methods, compositions, and kits of the invention are related to the discovery that lestaurtinib reduces levels and pathway activity of an SPOP substrate. Accordingly, described herein are methods and compositions for the use of lestaurtinib in downregulating one or more SPOP substrates or signaling pathway activities thereof in a subject in need thereof.Type: GrantFiled: December 3, 2014Date of Patent: October 10, 2017Assignee: Celestra Life Science LLCInventors: Allen J. Lee, Jason J. Lee, David M. Lu, Ruey-Min Lee
-
Patent number: 9782419Abstract: Dosing regimen for transdermal delivery of hormones comprising a variable treatment cycle and a variable rest interval.Type: GrantFiled: October 28, 2015Date of Patent: October 10, 2017Assignee: Agile Therapeutics, Inc.Inventors: Thomas M. Rossi, Marie Foegh, Agis Kydonieus
-
Patent number: 9782420Abstract: The present invention provides a pharmaceutical composition for removing drusen, suppressing formation of drusen, and/or treating and/or preventing age-related macular degeneration comprising the compound of formula (I) wherein Ra is independently selected from the group consisting of halo, hydroxy, alkyl, halo-substituted alkyl, aryl, halo- or alkyl-substituted aryl, alkoxy, hydroxy- or carboxy-substituted alkoxy, aryloxy, halo- or alkyl-substituted aryloxy, CHO, C(O)-alkyl, C(O)-aryl, C(O)-alkyl-carboxyl, C(O)-alkylene-carboxy ester and cyano, and m is an integer selected from 0 to 4.Type: GrantFiled: February 19, 2014Date of Patent: October 10, 2017Assignee: Kyoto UniversityInventors: Akira Kakizuka, Hanako Ikeda, Nagahisa Yoshimura, Yuki Muraoka
-
Patent number: 9782421Abstract: Complexes of neridronic acid, in an acid or a salt form, with amino acids, can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.Type: GrantFiled: May 4, 2017Date of Patent: October 10, 2017Assignee: ANTECIP BIOVENTURES II LLCInventor: Herriot Tabuteau
-
Patent number: 9782422Abstract: We describe a composition comprising a non-digestible oligosaccharide for the treatment, prevention or alleviation of a trichothecene mycotoxin exposure associated condition. The non-digestible oligosaccharide may comprise a galactooligosaccharide and/or fructooligosaccharide. The non-digestible oligosaccharide may comprise a short chain galacto-oligosaccharide (scGOS) and/or short chain fructooligosaccharide (scFOS). The trichothecene mycotoxin exposure associated condition may be associated with exposure to deoxynivalenol.Type: GrantFiled: May 17, 2013Date of Patent: October 10, 2017Assignee: N.V. NutriciaInventors: Johan Garssen, Hermiena Christina Schoterman, Johanna Fink-Gremmels, Saskia Braber
-
Patent number: 9782423Abstract: The invention relates to products comprising an antibiotic agent and a second agent being a dispersant or an anti-adhesive agent, in particular a mucolytic dispersant or a mucolytic anti-adhesive agent, which are useful in relation to the prevention and treatment of bacterial infections.Type: GrantFiled: June 1, 2012Date of Patent: October 10, 2017Assignee: Novabiotics LimitedInventors: Deborah O'Neil, Cedric Charrier
-
Patent number: 9782424Abstract: The present invention includes a composition comprising an effective amount of an avermectin compound, and an effective amount of an imidazole antifungal compound, and/or an effective amount of non-steroidal anti-inflammatory drug (NSAID) or suitable pharmaceutically acceptable salts thereof, for use in the inhibition of tumor growth and treating urothelial, colorectal, prostate and/or breast cancers. Furthermore, the invention includes a method of inhibiting tumor growth and treating said cancers comprising administering to a subject in need thereof an effective amount of said composition.Type: GrantFiled: December 20, 2012Date of Patent: October 10, 2017Assignee: ECTIN RESEARCH ABInventors: Christer Edlund, Peter Falk, Marie-Lois Ivarsson
-
Patent number: 9782425Abstract: Methods and compositions for safe and effective treatment of papulopustular rosacea in a subject are described. The methods involve topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. Treatment with ivermectin represents an innovative therapy that is more robust and effective than the conventional treatments.Type: GrantFiled: July 8, 2014Date of Patent: October 10, 2017Assignee: Galderma S.A.Inventors: Jean Jacovella, Jean-Paul Chappuis, Alexandre Kaoukhov, Michael Graeber, Laurence Salin, Michel Poncet, Philippe Briantais
-
Patent number: 9782426Abstract: This invention relates to a topical composition for prevention and treatment of viral infections.Type: GrantFiled: June 2, 2016Date of Patent: October 10, 2017Assignee: Cutanea Life Sciences, Inc.Inventors: Linda M. Mahoney, Anne T. Moore, Gary Lee Feiss, Danielle N. Ringhoff
-
Patent number: 9782427Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor having the following formula (I): and an effective amount of a cytidine analog, such as 5-azacytidine, to a patient having a cancer.Type: GrantFiled: April 16, 2014Date of Patent: October 10, 2017Assignee: Signal Pharmaceuticals, LLCInventor: Heather Raymon
-
Patent number: 9782428Abstract: Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.Type: GrantFiled: March 18, 2014Date of Patent: October 10, 2017Assignee: Northeastern UniversityInventors: Michail V. Sitkovsky, Robert Koehler Abbott, Stephen Matthew Hatfield
-
Patent number: 9782429Abstract: The present innovation relates to a novel formulation capable of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the formulation is characterized in that it contains defibrotide in combination with at least one haematopoietic factor having the capacity to mobilize haematopoietic progenitors, preferably G-CSF. In one embodiment, the formulation includes two separately administrable formulations, one containing a haematopoietic factor having the capacity to mobilize haematopoietic progenitors and the other containing defibrotide. The formulation is effective to achieve an increase in the number of haematopoietic progenitor cells that is greater than an increase in the number of haematopoietic progenitor cells achieved by the haematopoietic factor alone.Type: GrantFiled: July 3, 2014Date of Patent: October 10, 2017Assignee: GENTIUM S.R.L.Inventors: Laura Ferro, Roberto Porta, Massimo Iacobelli, Alessandro Massimo Gianni, Carmelo Carlo Stella
-
Patent number: 9782430Abstract: A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting an oxidized cellulose embolization solution into a lumen of a blood vessel to form an embolism within the lumen. The oxidized cellulose is present in an amount from about 10 % by weight to 20 % by weight of the oxidized cellulose embolization solution. The method also includes adjusting recanalization time of the embolism, which may be adjusted by tailoring a degradation rate of the oxidized cellulose.Type: GrantFiled: April 23, 2015Date of Patent: October 10, 2017Assignee: Covidien LPInventors: Rachit Ohri, Phillip D. Blaskovich
-
Patent number: 9782431Abstract: The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides reduce body weight and fat accumulation in laboratory animals, and can therefore be used to prevent and treat obesity.Type: GrantFiled: September 16, 2015Date of Patent: October 10, 2017Assignee: Chang Gung Biotechnology Corp.Inventors: Yun-Fei Ko, Jan Martel, Jian-Ching Liau, I-Te Chang, Chien-Sheng Lee, Wei-Chang Wang, Chen-Yaw Chiu, Chih-Jung Chang, Chuan-Sheng Lin, Tsung-Ru Wu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, Ding-E Young
-
Patent number: 9782432Abstract: Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 1 or more. Other embodiments of the invention provide a therapeutic method for treating a wound in an animal comprising administering to an animal in need of such therapy, an effective amount of a copolymer as described herein.Type: GrantFiled: December 17, 2015Date of Patent: October 10, 2017Assignee: Rutgers, The State University of New JerseyInventors: Kathryn E. Uhrich, Sabrina S. Snyder
-
Patent number: 9782433Abstract: In one or more embodiments, the present invention relates to a substantially homogeneous miscible liquid adhesive composition comprising a relatively high number average molecular weight (Mn=6,000-10,000 g/mole) cyanoacrylate tri-telechelic star polymer having polyisobutylene chains terminated with cyanoacrylate groups (High-Ø(PIB-CA)3); 2-octyl cyanoacrylate (Oct-CA); and a relatively low molecular weight (Mn=1,000-4,000 g/mole) cyanoacrylate tri-telechelic star polymer having polyisobutylene chains terminated with cyanoacrylate groups (Low-Ø(PIB-CA)3). The Low-Ø(PIB-CA)3 compatibilizes the High-Ø(PIB-CA)3 and Oct-CA removing the need for a solvent. When the substantially homogeneous miscible liquid adhesive compositions of various embodiments are reacted with a nucleophile, such as water or an initiator, they form a polymer co-network suitable for any of a number of biomedical applications, from wound closure and healing of skin tissue, to sealant for surgical cuts.Type: GrantFiled: November 13, 2015Date of Patent: October 10, 2017Assignee: The University of AkronInventors: Joseph Kennedy, Istvan Szanka, Amalia Szanka
-
Patent number: 9782434Abstract: Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.Type: GrantFiled: July 7, 2015Date of Patent: October 10, 2017Assignee: Sonoma Pharmaceuticals, Inc.Inventors: Hojabr Alimi, Andrés Gutiérrez
-
Patent number: 9782435Abstract: Composites and methods of producing a mouldable bone substitute are described. A scaffold for bone growth comprises nanocrystalline hydroxyapatite (HA), a bioresorbable plasticizer, and a biodegradable polymer. Plasticizers of the invention include oleic acid, tocopherol, eugenol, 1,2,3-triacetoxypropane, monoolein, and octyl-beta-D-glucopyranoside. Polymers of the invention include poly(caprolactone), poly(D,L-Lactic acid), and poly(glycolide-co lactide). Methods of regulating porosity, hardening speed, and shapeability are also described. Composites and methods are described using nanocrystalline HA produced with and without amino acids. The scaffold for bone growth described herein displays increased strength and shapeability.Type: GrantFiled: June 12, 2015Date of Patent: October 10, 2017Assignee: Promimic ABInventors: Per Kjellin, Paul Handa
-
Patent number: 9782436Abstract: Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.Type: GrantFiled: April 23, 2013Date of Patent: October 10, 2017Assignee: LifeCell CorporationInventor: Wenquan Sun
-
Patent number: 9782437Abstract: Disclosed herein are methods and compositions for targeted cleavage of a genomic sequence, targeted alteration of a genomic sequence, and targeted recombination between a genomic region and an exogenous polynucleotide homologous to the genomic region. The compositions include fusion proteins comprising a cleavage domain (or cleavage half-domain) and an engineered zinc finger domain and polynucleotides encoding same. Methods for targeted cleavage include introduction of such fusion proteins, or polynucleotides encoding same, into a cell. Methods for targeted recombination additionally include introduction of an exogenous polynucleotide homologous to a genomic region into cells comprising the disclosed fusion proteins.Type: GrantFiled: July 31, 2014Date of Patent: October 10, 2017Assignee: Sangamo Therapeutics, Inc.Inventors: Michael C. Holmes, Fyodor Urnov
-
Patent number: 9782438Abstract: Disclosed are a method of promoting hair growth or preventing hair loss in a mammal. In one aspect, the method includes administering interdermally or subcutaneously an agent containing an active ingredient comprising bFGF and a pharmaceutically acceptable substance, wherein bFGF is administered in a dose of 1 ?g to 100 ?g per 1 cm2 of the target area of hair growth treatment or hair loss prevention and a composition for use in the method.Type: GrantFiled: July 17, 2015Date of Patent: October 10, 2017Assignee: H CELL, INC.Inventor: Jaehyun Lim
-
Patent number: 9782439Abstract: Mesenchymal stem cells are pluripotent cells capable of differentiating into myocardial and vascular endothelial cells. The present invention demonstrates that the mesenchymal stem cell sheet have therapeutic potential for a severely damaged heart due to its pluripotency and in situ self-renewal capability. Mesenchymal stem cells derived from adipose tissue were cultured to prepare a mesenchymal stem cell sheet. Four weeks after induction of myocardial infarction in rats, the mesenchymal stem cell sheet was transplanted to the heart. The mesenchymal stem cell sheet were readily engrafted to the surface of the scarred myocardium, grew gradually in situ, and formed a thick layer (approximately 600 ?m) in 4 weeks. The grown transplanted mesenchymal tissue contained newly formed blood vessels, myocardial cells, and undifferentiated mesenchymal cells.Type: GrantFiled: January 27, 2006Date of Patent: October 10, 2017Assignee: JAPAN HEALTH SCIENCES FOUNDATIONInventors: Noritoshi Nagaya, Hidezo Mori, Yoshinori Miyahara
-
Patent number: 9782440Abstract: One aspect of the present disclosure can include a therapeutic composition useful for treatment of a genitourinary disorder. The composition can be derived from a culture media having been in contact with a population of bone marrow-derived mesenchymal stem cells for a sufficient time period necessary to endow therapeutic activity in the culture media. The therapeutic property endowed to the culture media is the ability to promote structural and functional recovery of a dysfunctional organ or biological tissue associated with the genitourinary disorder.Type: GrantFiled: February 19, 2013Date of Patent: October 10, 2017Assignee: The Cleveland Clinic FoundationInventors: Margot S. Damaser, Charuspong Dissaranan, Howard B. Goldman, Matthew Kiedrowski, Marc S. Penn
-
Patent number: 9782441Abstract: Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof.Type: GrantFiled: July 10, 2012Date of Patent: October 10, 2017Assignee: Albert Einstein College of Medicine, Inc.Inventors: Chandan Guha, Subhrajit Saha, Alan A. Alfieri, Payel Bhanja
-
Patent number: 9782442Abstract: Methods for preparing capsules, such as micro- and/or nanocapsules from all-aqueous emulsions are described herein. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute with at least an optionally charged second phase containing a second solute. The solutes are incompatible with each other. The electrostatic forces between the two solutions induce the formation of droplets of a dispersed phase in a continuous phase. The droplets are then solidified to form the capsules.Type: GrantFiled: December 9, 2014Date of Patent: October 10, 2017Assignee: Versitech LimitedInventors: Ho Cheung Shum, Yang Song
-
Patent number: 9782443Abstract: The usage of a stem cell in preparation of a tooth-like structure is provided. And a culture medium, a method for preparing an epithelial-like cell, a kit for preparing an ameloblast, a method for preparing an ameloblast are also provided. Specifically, the culture medium comprises a basal medium, which is DMEM/F12 medium; N2 supplement; retinoic acid; and BMP-4.Type: GrantFiled: February 5, 2013Date of Patent: October 10, 2017Assignee: Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of SciencesInventors: Duanqing Pei, Jinglei Cai, Pengfei Liu, Shubin Chen, Yanmei Zhang
-
Patent number: 9782444Abstract: The present invention relates to a method for fermenting fish skin by using Aspergillus. Also provided is a use of the fermentation liquid obtained by fermenting fish skin with Aspergillus obtained from the method in inhibiting the activity of tyrosinase, inhibiting the activity of angiotensin-converting enzyme and/or improving the survival of fibroblasts.Type: GrantFiled: May 24, 2016Date of Patent: October 10, 2017Assignee: FOOD INDUSTRY RESEARCH AND DEVELOPMENT INSTITUTEInventors: Shu-Chen Huang, Pei-Jou Liu, Chiao-Ming Liao, Hing-Yuen Chan
-
Patent number: 9782445Abstract: Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag.Type: GrantFiled: May 8, 2015Date of Patent: October 10, 2017Assignee: Rebiotix, Inc.Inventors: Lee A. Jones, Courtney R. Jones, Mary Kay Sobcinski
-
Patent number: 9782446Abstract: Disclosed are novel Lactobacillus plantarum strains as well as a composition containing the novel Lactobacillus plantarum strains or a culture thereof.Type: GrantFiled: February 8, 2016Date of Patent: October 10, 2017Assignee: AMOREPACIFIC CORPORATIONInventors: Il Young Kwack, Se Jin You, Tae-Hun Park, Bum Jin Lee, Kye Ho Shin, Jin Oh Chung, Jun Cheol Cho
-
Patent number: 9782447Abstract: The present invention provides a method to prepare polysaccharides from Hirsutella sinensis. The prepared polysaccharides can reduce liver size, weight and the number and size of liver lipid vacuoles, as well as serum triglycerides and serum aspartate aminotransferase levels in humans and animals. The prepared polysaccharides can therefore be used to prevent and treat fatty liver disease.Type: GrantFiled: September 16, 2015Date of Patent: October 10, 2017Assignee: Chang Gung Biotechnology Corp.Inventors: Yun-Fei Ko, Jan Martel, Jian-Ching Liau, I-Te Chang, Chien-Sheng Lee, Wei-Chang Wang, Chen-Yaw Chiu, Chih-Jung Chang, Chuan-Sheng Lin, Tsung-Ru Wu, Chia-Chen Lu, David Marcelo Ojcius, Hsin-Chih Lai, Ding-E Young
-
Patent number: 9782448Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.Type: GrantFiled: August 2, 2013Date of Patent: October 10, 2017Assignee: ELC Management LLCInventors: Donald F. Collins, Daniel H. Maes, Neelam Muizzuddin
-
Patent number: 9782449Abstract: A method for the treatment of addiction to tobacco includes the stages of i) interviewing and training of a tobacco user (patient) and an accompanying person (ii) undergoing a Domiciliary Intensive Detoxification Program, including breathing and corporal exercises, directed balneotherapy, dietary measures including the intake of selected groups of foods and aloe vera gel, hygienic and oral rehabilitation measures and (iii) adhering to a maintenance program.Type: GrantFiled: July 27, 2012Date of Patent: October 10, 2017Assignee: AMERICAN LIFE NATURALLYInventor: Pabla Beatriz Rojas de Naguila
-
Patent number: 9782450Abstract: Disclosed are methods of managing obesity and hypercholesterolemia using a composition of matter comprising the ethyl acetate fraction of the extract of Cyperus rotundus rhizomes standardized to contain 5% of total stilbenes.Type: GrantFiled: May 6, 2015Date of Patent: October 10, 2017Assignee: SAMI LABS LIMITEDInventors: Muhammed Majeed, Kalyanam Nagabhushanam, Douglas Kalman, Beena Bhat, Priti Vaidyanathan, Sarang Bani, Anjali Pandey, Suresh Karri
-
Patent number: 9782451Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.Type: GrantFiled: September 14, 2016Date of Patent: October 10, 2017Assignee: Celgene CorporationInventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
-
Patent number: 9782452Abstract: This disclosure demonstrates that blockade of TGF? signaling after a hematopoietic stress (e.g., chemotherapy, transplantation, and infection) accelerates hematopoietic reconstitution and delays the return of cycling hematopoietic stem and progenitor cells (HSPCs) to quiescence. TGF? blockade in these settings promotes multilineage hematopoietic regeneration by prolonging HSPC cycling and by promoting HSC self-renewal, and is useful for treating hematologic deficiencies caused various hematopoietic stresses.Type: GrantFiled: November 21, 2012Date of Patent: October 10, 2017Assignee: Cornell UniversityInventors: Joseph Scandura, Fabienne Brenet
-
Patent number: 9782453Abstract: The invention concerns the use of hepcidin for the diagnosis and therapy of disorders of iron homeostasis. Hepcidin can be used in the treatment of disorders resulting from iron overload, while inhibitors of hepcidin can he used in the treatment of anaemia.Type: GrantFiled: June 23, 2015Date of Patent: October 10, 2017Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Gael Nicolas, Sophie Vaulont, Axel Kahn
-
Patent number: 9782454Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.Type: GrantFiled: April 22, 2011Date of Patent: October 10, 2017Assignee: LONGEVITY BIOTECH, INC.Inventors: Scott J. Shandler, Samuel H. Gellman